SAVE

Safe Save Medical Cell Sciences & Technology is a Taiwan-based cancer immunotherapy company focused on autologous dendritic cell-based treatments. The company’s core platform, Autologous Dendritic Cells/Tumor Antigens (ADCTA), is being developed as a personalized immunocell therapy approach for glioblastoma and other solid tumors. Its lead program, ADCTA-SSC-G1, has advanced into Phase 3 clinical development for recurrent glioblastoma in Taiwan, supported by multicenter hospital collaborations. The company also positions ADCTA as a broader platform for expansion into lung, colorectal, breast, ovarian, pancreatic, and other refractory solid tumors. In 2026, YD Bio announced a binding letter of intent to acquire the company, and third-party databases classify it as acquired by YD Bio.